SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 107.98 |
| Enterprise Value ($M) | 77.72 |
| Book Value ($M) | 38.67 |
| Book Value / Share | 1.74 |
| Price / Book | 2.79 |
| NCAV ($M) | 21.74 |
| NCAV / Share | 0.98 |
| Price / NCAV | 4.97 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.99 |
| Return on Assets (ROA) | -0.66 |
| Return on Equity (ROE) | -0.92 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.59 |
| Current Ratio | 2.59 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 35.85 |
| Assets | 52.78 |
| Liabilities | 14.11 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Highbridge Capital Management Llc | 6.60 | ||
| 13G/A | Xencor Inc | 9.60 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 38,217 | 169,206 | 22.59 | |
| 39,402 | 122,236 | 32.23 | |
| 67,383 | 180,332 | 37.37 | |
| 68,865 | 178,773 | 38.52 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| INDP – Indaptus Therapeutics, Inc. | INKT – MiNK Therapeutics, Inc. |
| INM – InMed Pharmaceuticals Inc. | INTS – Intensity Therapeutics, Inc. |
| IRD – Opus Genetics, Inc. |
Financial data and stock pages provided by
Fintel.io